DNA methylation clocks capture biological aging state
PrimaryMyAgingTests' core causal theory is that DNA methylation patterns change with aging in ways that quantify biological age, age acceleration, or pace of aging. Therefore, assays such as GrimAge, PhenoAge, and DunedinPACE can act as biomarkers for longevity intervention testing, clinical follow-up, research cohorts, and longitudinal tracking. Testable predictions are that people with higher epigenetic age acceleration or faster DunedinPACE will show worse aging-related risk profiles over time, while effective longevity interventions should reduce age acceleration or slow measured pace of aging on repeat testing.
Popperian evaluation
The core premise is credible: DNA methylation patterns track chronological age well enough to build clocks, and several clocks also correlate with disease burden or physiological risk. The weak part is the causal jump. A clock can read aging-related methylation without proving that the methylation pattern itself is the aging state.
Supporting evidence: GrimAge, PhenoAge, and DunedinPACE are presented as methylation-based measures of biological age, age acceleration, or pace of aging.; The polar bear methylation clock estimated known chronological age with r = 0.97 and a median absolute error of about 9 months, which supports the general claim that methylation encodes age-related information.; Adults with moderate and complex congenital heart disease showed PhenoAge acceleration, GrimAge2 acceleration, and higher DunedinPACE than matched healthy controls.
Counter evidence: The evidence supports measurement and association more strongly than causation.; The theory assumes that clock outputs capture biological aging state rather than tissue composition, assay noise, inflammation, medication exposure, or other methylation variation.
The theory explains several observations cleanly: older organisms have predictable methylation patterns, sicker adults can show older methylation profiles, and some interventions can move clock readouts. Still, alternative explanations remain alive. Disease stress, immune-cell shifts, and short-term metabolic changes could move these assays without changing the underlying aging process.
Supporting evidence: In the AccelerAGE study, moderate congenital heart disease was associated with PhenoAge acceleration of +3.0 years and complex disease with +5.5 years.; The same study reported GrimAge2 acceleration of +2.1 years in moderate disease and +2.3 years in complex disease.; Caloric restriction was reported to slow DunedinPACE, matching the prediction that an effective longevity intervention should reduce measured pace of aging.
Counter evidence: Semaglutide reducing PhenoAge acceleration is listed with low confidence, so it cannot carry much explanatory weight.; The congenital heart disease result may reflect disease burden and systemic vulnerability rather than a general biological aging state.; We do not fully know when a clock shift means slower aging rather than a changed blood-cell mix or acute treatment response.
The theory makes testable claims. Higher age acceleration should predict worse aging-related risk over time, faster DunedinPACE should track worse longitudinal profiles, and effective interventions should reduce acceleration or pace on repeat testing. Those claims can fail in prospective cohorts or randomized trials.
Supporting evidence: The theory predicts worse aging-related risk profiles in people with higher epigenetic age acceleration.; It predicts worse risk profiles in people with faster DunedinPACE.; It predicts that effective longevity interventions should reduce epigenetic age acceleration or slow measured pace of aging on repeat testing.
Counter evidence: The theory needs prespecified thresholds for meaningful change, assay variability, tissue source, follow-up interval, and clinical endpoints.; A vague claim that clocks are useful for follow-up is easier to rescue after the fact than a hard prediction tied to morbidity, mortality, or functional decline.
Reasoning tree
Public endorsements
The named "person" is "Our Mission," which is not an identifiable individual, and the dossier includes no attributed quote or publication from a real founder. The available records describe Clock Foundation and MyAgingTests' use of epigenetic clocks, but they do not show this specific person publicly endorsing, mentioning, or contradicting the theory.
Robert T. (Bobby) Brooke co-founded the Epigenetic Clock Development Foundation with Steve Horvath, and the provided event bio says the foundation is dedicated to enabling rigorous, widespread use of epigenetic clocks and other aging biomarkers, especially for testing longevity interventions. That is a direct public endorsement of the theory that DNA methylation clocks capture biological aging state and are useful for intervention tracking.
Horvath publicly endorses the core claim. He says biological age can be measured from a simple saliva sample, links vegetable intake to epigenetic clock readouts, and is credited with developing the original Horvath clock, one of the first tools built on the idea that DNA methylation carries a reliable aging signal across tissues. That is direct support for methylation clocks as biological aging biomarkers.